---
title: "Causal Roadmap Tutorial: Summary & Next Steps"
format: pptx
---

## Overview

-   Review: Tutorial implementing the **Causal Roadmap** for AKI risk after HCV treatment
-   Focus: From causal question → estimand → identification → estimation → interpretation
-   Tools: `lmtp`, `concrete`, `tmle3`, Super Learner

------------------------------------------------------------------------

## Step 1a: Causal Question & Estimand

-   Main estimand: 90-day **risk difference** of AKI under `SOF` vs `non-SOF` regimens
-   Strategy: *Hypothetical* no-switch design
-   Defined intercurrent events:
    -   Regimen switching → censor at switch
    -   Death → competing risk (Fine-Gray planned)

------------------------------------------------------------------------

## Step 1b: Causal Model

-   DAG encoded time-varying structure:
    -   Treatment ↔ time-varying lab + comorbidity status
    -   Adherence varies by drug/tolerability
-   Identification conditions explicitly stated:
    -   Exchangeability, consistency, positivity, non-informative censoring

------------------------------------------------------------------------

## Step 2: Observed Data

-   Retrospective claims data structured into 90-day intervals
-   Variables:
    -   Baseline: Age, sex, liver/kidney history, HCV genotype
    -   Time-varying: labs (eGFR), drugs, adherence (PDC), censoring

------------------------------------------------------------------------

## Step 3: Identification Assumptions

-   No unmeasured confounding → claims data only approximate this
-   Positivity check: P(A = a \| W) \> 0 ∀a, W ➜ diagnostic plots under development
-   Censoring: IPCW approach included for sensitivity analysis

------------------------------------------------------------------------

## Step 4: Statistical Estimand

-   Primary:
    -   Risk at 90 days under `SOF` and under `non-SOF` if no switch occurs
-   Secondary:
    -   ITT estimand (no censoring at switch)
    -   Cumulative incidence under competing risk

------------------------------------------------------------------------

## Step 5: Estimation

-   Used `concrete::doConcrete()` for one-step TMLE
-   Outcome regression: SL with GLM, random forest, HAL
-   Targeted updates yield influence-function–based standard errors

------------------------------------------------------------------------

## Step 6: Sensitivity Analyses

-   IPCW for informative censoring at switch
-   Alternative outcome definition (stricter AKI diagnosis code)
-   Compare TMLE vs Cox HR
-   Consider per-protocol via dynamic shift in `lmtp`

------------------------------------------------------------------------

## Key Takeaways

-   Roadmap improves clarity & transparency
-   TMLE/SDR estimators give interpretable, valid estimates
-   `{lmtp}` offers flexibility for dynamic & stochastic adherence policies
-   `{concrete}` enables valid inference for time-to-event contrasts

------------------------------------------------------------------------

## Next Steps

-   Finalize diagnostic plots for positivity, model diagnostics
-   Publish `R Markdown` companion and harmonize TMLE vs `lmtp` estimands
-   Develop simulation-based validation: how close do our estimators recover truth?
-   Explore incorporation of competing risk CIF using `lmtp_sdr(..., compete =)`
-   Submit methods summary to regulatory engagement workstream

------------------------------------------------------------------------
